Miguel Cordero Coma

Dr. Miguel Cordero Coma


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Survey of Ophthalmology
Verified
Journal Article
Closed access
MCMiguel Cordero Coma
Miguel Cordero Coma
LSLucia Sobrin
Lucia Sobrin

28 May 2014 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
MCMiguel Cordero Coma
Miguel Cordero Coma
VCVanesa Calvo-Río
Vanesa Calvo-Río
AAAlfredo Adan
Alfredo Adan
RBRicardo Blanco
Ricardo Blanco
CÁCarolina Álvarez-Castro
Carolina Álvarez-Castro
JMJosé G. Ruíz de Morales
José G. Ruíz de Morales
Objective. To evaluate, in three Spanish tertiary referral centres, the short-term safety and efficacy of golimumab (GLM) for treatment of immune-mediated uveitis resistant to previous immunosuppressive therapy.Methods. Nonrandomized retrospective interventional case series. Thirteen patients with different types of uveitis that were resistant to treatment with at least 2 previous immunosuppressors were included in this study. All included patients were treated with GLM (50 mg every four weeks) during at least 6 months. Clinical evaluation and treatment-related side effects were assessed at least four times in all included patients.Results. Eight men and 5 women (22 affected eyes) with a median age of 30 years (range 20–38) and active immune-mediated uveitides were studied. GLM was used in combination with conventional immunosuppressors in 7 patients (53.8%). GLM therapy achieved complete control of inflammation in 12/13 patients (92.3%) after six months of treatment. There was a statistically significant improvement in mean BCVA (0.60 versus 0.68,P=0.009) and mean 1 mm central retinal thickness (317 versus 261.2 μ,P=0.05) at the six-month endpoint when compared to basal values. No major systemic adverse effects associated with GLM therapy were observed.Conclusions. GLM is a new and promising therapeutic option for patients with severe and refractory uveitis.

16 January 2013 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
MCMiguel Cordero Coma
Miguel Cordero Coma
TYTaygan Yilmaz
Taygan Yilmaz
SOSumru Onal
Sumru Onal
Purpose: To establish evidence-based recommendations regarding the use of anti-Tumor Necrosis Factor alpha (TNF-α) agents for managing uveitis patients. Methods: Medline was searched via OVID (1950 – October Week 3, 2011) using a Cochrane highly sensitive search (phases 1 and 2). Additional literature searches were also conducted incuding the following databases: the Cochrane, LILACS and the TRIP Database. Results: A total of 54 studies met all of the inclusion criteria and were included in this review. A different level of recommendation and evidence is assigned to each anti-TNF-α agent. The overall rate of reported side effects with anti-TNF-α agents for the treatment of uvetis which required discontinuation of therapy was 2.2% (26/1147 patients). Conclusion: Based on the evidence gathered, infliximab and adalimumab seem to be effective in the management of immune-mediated uveitis. Further randomized studies evaluating the efficacy of these agents are warranted.

17 October 2014 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
MCMiguel Cordero Coma
Miguel Cordero Coma
RSRaquel Salazar-Méndez
Raquel Salazar-Méndez
IGIrene Garzo-García
Irene Garzo-García
TYTaygan Yilmaz
Taygan Yilmaz
Drug-induced uveitis is a well described but often overlooked and/or misdiagnosed adverse reaction to medication. There are an increasing number of medications that have been related to the onset of intraocular inflammation. Identification of these inciting agents may decisively help the diagnostic algorithm involving new cases of uveitis. This review intends to be an updated comprehensive, practical guide for practitioners regarding the main drugs that have been associated with uveitis. A classification proposed by Naranjo et al. in 1981 for establishing potential causality is applied examining possible mechanisms of action. A guide for clinicians about the rationale of these observations when dealing with patients with uveitis is provided. Several agents with different routes of administration (systemic, topical and/or intraocular) may cause intraocular inflammation. The mechanism behind ocular inflammation is frequently unknown. Clinicians should be aware of the potential drug effect to optimize diagnosis and management of such patients.

1 October 2017 in Medicine
Verified
Journal Article
Open access
PDF file
AGAlejandro Gómez-Gómez
Alejandro Gómez-Gómez
ELEstíbaliz Loza
Estíbaliz Loza
MRMaria Piedad Rosario
Maria Piedad Rosario
GEGerard Espinosa
Gerard Espinosa
JMJosé M. García Ruiz de Morales
José M. García Ruiz de Morales
MCMiguel Cordero Coma
Miguel Cordero Coma
To assess the efficacy and safety of immunomodulatory drugs in patients with noninfectious anterior uveitis (AU). Systematic review of studies were retrieved from Medline (1961 to March 2016), Embase (1961 to March 2016), and Cochrane Library (up to March 2016), and a complementary hand search was also performed. The selection criteria were as follows: (population) noninfectious AU patients, adults; (intervention) immunomodulatory drugs (any dose, regimen, route of administration, duration of treatment); (outcome) control of inflammation, steroid-sparing effect, AU flares, adverse events, and so on; (study design) systematic literature reviews, randomized controlled trials, and observational studies. The study quality was assessed using the Jadad scale and according to The Oxford Centre for Evidence-based Medicine (update 2009). We included 13 studies of moderate-poor quality, with a mean duration from 5 months to 20 years, and number of AU patients ranging from 9 to 274. Patient's demographic and clinical characteristics were very heterogeneous. In most cases, uveitis anatomic classification criteria and outcomes definitions were unclear. Some of the studies only included AU patients with a systemic disease associated, mostly spondyloarthritis, others, mixed populations (idiopathic and systemic disease associated patients), and in some articles this data is not described. We found that methotrexate, cyclosporine A, azathioprine, adalimumab, and golimumab might prevent AU flares, improve ocular inflammation and visual acuity, and decrease systemic steroids doses. Although there is a lack of robust evidence, methotrexate, cyclosporine A, azathioprine, adalimumab, and golimumab might be effective in AU patients.

1 December 2017 in Medicina Clinica
Verified
Journal Article
Closed access
Gerard EspinosaGerard Espinosa
Gerard Espinosa
SMSantiago Muñoz-Fernández
Santiago Muñoz-Fernández
JMJosé M. García Ruiz de Morales
José M. García Ruiz de Morales
JHJosé M. Herreras
José M. Herreras
MCMiguel Cordero Coma
Miguel Cordero Coma